PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 213/82, 241/44, 215/48, 261/18, 277/68, 239/74, 333/38, 401/12, 401/14, 413/12, 213/81, A61K 31/44, 31/47, 31/495

A1

(11) International Publication Number: **WO 00/07991**

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/GB99/02489

(22) International Filing Date: 29 July 1999 (29.07.99)

(30) Priority Data:

9816838.8	4 August 1998 (04.08.98)	GB
9824939.4	13 November 1998 (13.11.98)	GB

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: BROWN, Dearg, Sutherland [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). BROWN, George, Robert [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: TAIT, Brian, Steele; Astra Zeneca PLC, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES



(I)

(57) Abstract

The invention concerns amide derivatives of formula (I) wherein R^3 is (1–6C)alkyl or halogeno; Q^1 is heteroaryl which is optionally substituted with 1, 2, 3, or 4 substituents such as hydroxy, halogeno, trifluoromethyl, (1–6C)alkyl, (1–6C)alkoxy, hydroxy–(1–6C)alkyl, (1–6C)alkoxy–(1–6C)alkyl, hydroxy–(2–6C)alkoxy, amino–(2–6C)alkylamino, N–(1–6C)alkyl–(1–6C)alkylamino–(2–6C)alkylamino, aryl, heteroaryl and heterocyclyl; p is 0–2 and R^2 is a substituent such as hydroxy and halogeno; q is 0–4; and Q^2 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically–acceptable salts or *in vivo*–cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.